{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:58Z","timestamp":1790186518191,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015277","name":"Roche UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jns.2026.126159","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:08:19Z","timestamp":1788480499000},"page":"126159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["UK SMA patient registry: a 3-year patient-reported outcome measures study supporting the drug appraisal of Nusinersen and Risdiplam in spinal muscular atrophy"],"prefix":"10.1016","volume":"490","author":[{"given":"Aleks","family":"Carver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Karkkainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Muni-Lofra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grecia","family":"Benesperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionne","family":"Moat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Simms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennadiy","family":"Ilyashenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McConville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andria","family":"Merrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Parton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Thorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Rohwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Ryburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channa","family":"Hewamadduma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare M.","family":"Galtrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marini-Bettolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2026.126159_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jns.2026.126159_bb0010","author":"Authority NHR"},{"key":"10.1016\/j.jns.2026.126159_bb0015","author":"Network T-NN"},{"key":"10.1016\/j.jns.2026.126159_bb0020","series-title":"Managed Access Agreement. Nusinersen (Spinraza) for the treatment of 5q spinal muscular atrophy","author":"Excellence NIfHaC","year":"2019"},{"key":"10.1016\/j.jns.2026.126159_bb0025","series-title":"Managed Access Agreement. Risdiplam for Treating Spinal Muscular Atrophy in Children and Adults","author":"Excellence NIfHaC","year":"2021"},{"issue":"7","key":"10.1016\/j.jns.2026.126159_bb0030","doi-asserted-by":"crossref","first-page":"A505","DOI":"10.1016\/j.jval.2016.09.922","article-title":"Managed access agreements: a new model pathway for the reimbursement of non-oncology drugs in England approved under European adaptive pathways?","volume":"19","author":"Macaulay","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jns.2026.126159_bb0035","series-title":"Interim Process and Methods of the Highly Specialised Technologies Programme (Updated to Reflect 2017 Changes)","author":"Excellence NIfHaC","year":"2017"},{"issue":"1","key":"10.1016\/j.jns.2026.126159_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01876-4","article-title":"Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement","volume":"16","author":"Stevens","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jns.2026.126159_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsad014","article-title":"Should Canada adopt managed access agreements in Canada for expensive drugs?","volume":"10","author":"McPhail","year":"2023","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.jns.2026.126159_bb0050","series-title":"SMA Expanded Dataset - Final Report (Year 4)","author":"Bohill","year":"2023"},{"key":"10.1016\/j.jns.2026.126159_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105341","article-title":"Assessing disease progression in spinal muscular atrophy, current gaps, and opportunities: a narrative review","volume":"49","author":"Muni-Lofra","year":"2025","journal-title":"Neuromuscul. Disord."},{"issue":"15","key":"10.1016\/j.jns.2026.126159_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","article-title":"Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community update survey","volume":"24","author":"Belter","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.jns.2026.126159_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JND-221595","article-title":"Patient reported outcome measures in adult spinal muscular atrophy: a scoping review and graphical visualization of the evidence","volume":"10","author":"Slayter","year":"2023","journal-title":"J. Neuromusc. Dis."},{"key":"10.1016\/j.jns.2026.126159_bb0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/hex.13254","article-title":"Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues","volume":"24","author":"Churruca","year":"2021","journal-title":"Health Expect."},{"issue":"3","key":"10.1016\/j.jns.2026.126159_bb0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/mus.28311","article-title":"Longitudinal efficacy of Nusinersen treatment on health-related quality of life and independence in children with later-onset spinal muscular atrophy","volume":"71","author":"Huang","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126159_bb0080","doi-asserted-by":"crossref","DOI":"10.2147\/PROM.S517362","article-title":"Agreement between child self- and parent proxy-reports of health-related quality of life in spinal muscular atrophy: preliminary insights from a nationwide patient registry in Germany","volume":"16","author":"Landfeldt","year":"2025","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.jns.2026.126159_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.104451","article-title":"Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec \u2013 the SMA REACH UK network experience","volume":"44","author":"Wolfe","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jns.2026.126159_bb0090","author":"REACH AS"},{"key":"10.1016\/j.jns.2026.126159_bb0095","series-title":"EQ-5D-5L User Guide","author":"Foundation ER","year":"2019"},{"key":"10.1016\/j.jns.2026.126159_bb0100","series-title":"EQ-5D-Y-3L User Guide","author":"Foundation ER","year":"2024"},{"key":"10.1016\/j.jns.2026.126159_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-023-02204-z","article-title":"Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy","volume":"21","author":"Xu","year":"2023","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jns.2026.126159_bb0110","series-title":"Spinal Muscular Atrophy Independence Scale (SMAIS) Upper Limb Module User Manual","author":"Staunton","year":"2021"},{"key":"10.1016\/j.jns.2026.126159_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105397","article-title":"Two-year Risdiplam treatment in adults with spinal muscular atrophy: improvements in motor and respiratory function, quality of life and fatigue","volume":"52","author":"Iterbeke","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jns.2026.126159_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120059","article-title":"Development of the SMA independence scale\u2013upper limb module (SMAIS\u2013ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA","volume":"432","author":"Trundell","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.126159_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-025-06207-4","article-title":"Italian validation of the SMA independence scale-upper limb module","volume":"184","author":"Bravetti","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.jns.2026.126159_bb0130","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study","volume":"29","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126159_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2026.126159_bb0140","series-title":"Technology Appraisal Guidence. Nusinersen and Risdiplam for Treating Spinal Muscular Atrophy","author":"Excellence NIfHaC","year":"2026"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:18:08Z","timestamp":1790183888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0022510X26004417"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126159","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UK SMA patient registry: a 3-year patient-reported outcome measures study supporting the drug appraisal of Nusinersen and Risdiplam in spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126159"}}